Abattis Bioceuticals Corp.
ATTBF · OTC
9/30/2019 | 9/30/2018 | 9/30/2017 | 9/30/2016 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 4,163.2% | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 67.6% | 77.4% | – | – |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -813.3% | -207,095.9% | – | – |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -852.4% | -931,940.1% | – | – |
| EPS Diluted | -0.007 | -0.24 | -0.051 | -0.025 |
| % Growth | 97.3% | -367.8% | -108.5% | – |
| Operating Cash Flow | $0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $0 | -$0 | -$0 | -$0 |